

INDEX

A

Absorption, distribution, metabolism, excretion and toxicity (ADMET) propertiesv, 403–414
 Adamantane derivativesv, 279–285
 Adenosine diphosphate (ADP)372, 374, 375, 382
 Aggregation1–3, 12, 17–29, 54, 55, 61, 344, 354, 373, 382, 384
 Alignments ...9, 74, 168, 327, 328, 352, 388, 394, 399, 400, 408, 413
 Aliphatic57, 93, 104, 355, 361, 418
 Allosteric site91
 Amastigotes143, 148, 149, 160
 AMBER36, 38–40, 199, 202, 205, 207, 208, 210, 213, 234, 292, 338, 363, 411
 Amyloidv, 2, 17, 18, 21, 22, 24, 27, 53, 57
 Angiotensin II type I receptor (AT1R)vi, 431–444, 449–459
 Antechamber40, 338
 Antiparasitic activity139
 Antiplatelet activity372, 381–382
 Arachidonic acid (AA)335, 374, 382
 Aromatic17–29, 57, 59, 93, 98, 100, 101, 173, 254, 260, 311, 349–351, 361, 364, 365, 390, 391, 393
 Arrhenius equation424
 Association rate186, 187, 189, 191
Avogadro99

B

BALBES98
 Benzylthiochalcones388, 389, 394
 Beta-sheet26
 Binding event
 ligand-protein binding50, 293
 peptide-protein binding287
 Binding site51, 60, 94, 96, 98, 99, 105–107, 165, 168, 169, 171, 202, 203, 207, 212, 230, 232, 233, 247, 249, 254, 259, 288, 292, 294, 311, 312, 317, 318, 321, 323–325, 337, 344, 351, 353, 355, 363, 364, 410, 411
 Biobanks108
 BIOIMAGING108
 Bioinformatics98, 133, 137, 261, 403, 432
 Bioisosteres253, 259

C

CASTp98
 Catalytic Site Atlas (CSA)98, 263
 Catalytic sites98
 CCP4 suite98, 99
 cDNA92, 251
 ChEMBL113
 Chemical Identifier Resolver (CIR)114, 131, 134
 Chemical synthesis373, 411, 412
 Cheminformaticsv, 6, 113–137, 261, 373, 375
 Chimera68–70, 72–75, 86, 98, 99, 230–232, 234, 235, 311
 Cholix toxin (CT)230
 Chromatography
 reversed-phase220
 ultra-high performance liquid373
 Circular dichroism spectroscopy (CD)94
 Co-activator
 recruitment assay255
 Co-crystallization94, 96, 105, 450
 Coefficient values125, 394
 Cofactors93, 98
 Competition association binding kinetics190
 Computational nanotoxicology113
 Computer-aided drug discovery (CADD)67, 263, 349, 350, 354
 Concentrations21, 23, 24, 50, 51, 54, 55, 57, 61, 62, 95, 96, 104, 105, 146–148, 150–153, 161, 179, 181, 182, 184, 186–188, 190–192, 218, 256, 258, 303, 304, 306, 309–313, 338, 339, 343, 374, 375, 378, 380, 383, 418, 425, 427
 Conformational analysis5, 76, 337, 390, 405
 Conformational changes68, 105, 246, 300, 318, 319, 329, 418, 434
 Conformers6, 12, 72, 98, 107, 173, 356–358, 388, 409, 411, 412
 Confusion matrix119–121
 Consensus scoring function269–271, 328
 Construct design91, 102
 Coot98, 99
 Co-repressors246, 247
 Cross- β -sheet structure1
 Cryoprotectant96
 Crystal lattice96

- Crystallization 94–97, 104, 450
Crystallization plate 94
Crystal packing interactions 94
Crystal structure 25, 35, 36, 42, 91, 99,
231, 232, 266–268, 271, 272, 274, 323–325,
350, 351, 354, 359, 408, 413, 432, 434, 436,
437, 451, 452, 454–456
Cyclooxygenase 1 (COX-1) 373–375
Cytotoxicity 18, 141, 144, 149–152, 388, 389
- D**
- Data
collection 94, 96, 128
curation 114, 116
Databases
chemical 34, 35, 37, 38, 114, 115,
131–133, 136, 308, 353
DEPTH 98
Desmond Maestro 4, 6, 8, 9
Dimethyl sulfoxide (DMSO) 2, 4, 6, 7, 12–14,
21, 54, 96, 104, 147–150, 152, 153, 157, 158,
161, 179, 180, 190, 192, 252, 256, 257, 338,
380, 382–384, 421, 428
Diphtheria toxin (DT) 230, 231
Dissociation rate 179, 184, 186, 189, 191, 193
Docking, *see* Molecular docking
Docosahexaenoic (DHA) acid 372
Domain of applicability 114, 126, 127, 293
Drug 35, 49, 67, 90, 113, 139, 166, 193,
217, 245, 261, 279, 287, 300, 317,
348, 371
Drug design 12, 35, 67, 90, 113, 139, 230,
261, 287, 300, 349, 403, 417, 432
Drug discovery v, 50, 67, 91, 107, 108,
113–137, 196, 197, 199, 202–205, 208, 210,
212–214, 217–225, 229, 245, 261–263, 288,
317, 348, 349, 353, 354, 373, 387, 404, 419,
421, 432, 435, 449
Dundee server 99
Dynamic light scattering (DLS) 94
Dynamic undocking v, 196, 197, 199,
203–205, 208, 210, 212–214
- E**
- Electron microscopy (EM) 22, 90, 352
Enalos+
Kennard and Stone node 119, 128, 129
KNIME nodes 113–137
Model Acceptability Criteria 125, 127–130
PubChem nodes 132, 133
sphere exclusion node 129
UniChem nodes 116, 133, 134
Y-Randomization node 125, 127
- Energy minimization 4, 39, 86, 99, 106,
169, 207, 300, 308, 326, 356, 360, 443
Epigenetic targets 349
Epitope mapping 50, 51, 55, 59
Exotoxin A (ETA) 230, 231
Expression systems 92, 93, 104
- F**
- Farnesoid X receptor (FXR) 246, 247, 249,
252, 253, 258, 259
Fatty acid mimetic 248, 249, 252
FDA 118, 348, 372
Feature frequencies 329, 396, 399
Firefly luciferase 251, 252
Flavonoids 372, 375
Flow cytometry 381, 382
Fluorescence resonance energy transfer (FRET)
time resolved 177
Fluorescent ligand 182, 184, 186–188, 192, 193
Folding 2, 91–94, 102, 303
Formulation 145, 154
Fpocket 98
Fragment-based discovery (FBD) 106
Frequency-based ranking 261
- G**
- Gal4 hybrid receptor 251, 253–258
Glycosylation 94
G protein-coupled receptors (GPCRs) 91, 166–171,
199, 289, 290, 431–444, 449–452, 455
Graphical Processing Unit (GPU) 8, 9,
289–291, 294
Grignard reagents 281, 283–285
GROMACS 292, 406, 438, 439, 443, 444
- H**
- Hanging drop 104
Hexafluoro-2-Propanol (HFIP) 4, 6–9, 12, 14, 21
High resolution 24, 74, 96, 108, 324, 418
High-throughput screening (HTS) 91, 106, 113,
263, 432
Histone deacetylases (HDACs) 349, 406, 408–409
Homology modeling 168, 172, 408–409, 449
Human Islet Amyloid Polypeptide (hIAPP)
hIAPP22-29 2, 18, 19, 21
Human plasma stability 384
Hybrid reporter gene assay 251, 253–258
Hydrogen bonds 16, 24, 34, 45, 98, 99,
107, 108, 170, 196, 198, 199, 202–205, 207,
208, 214, 225, 234, 262, 273, 311, 360, 375,
390–393, 395, 405, 452, 456
Hydrophilicity 96
Hydrophobicity 24, 96, 221, 262

I

- Imidazole 104, 142, 146, 302
In silico v, 2–4, 33–39, 98, 114, 120,
126, 261–275, 287, 299–314, 317, 349, 372,
373, 409–412, 436, 440, 449–459
In situ formation 422, 428
INSTRUCT-ERIC 108
Integrative structural biology 90–108
Intermolecular β -sheets 1, 2
Intersite distance 391, 399
Inversion recovery experiment 423
Isoelectric point 93, 218
i-TASSER 102, 408, 413

K

- K562 cell 388
Konstanz Information Miner (KNIME) 114–119,
125–127, 131–134, 136, 137, 327

L

- Lattice, *see* Crystal lattice
Ligand 44, 50, 67, 91, 114, 165,
177, 219, 230, 245, 262, 279, 287, 299, 317,
337, 349, 387, 404, 418, 432, 452
Ligand-based
 drug design 91, 98, 404
 virtual screening 68, 114, 318, 328, 349, 439
Ligand binding
 affinity 50, 93, 95, 99, 105–107, 165,
 192, 193, 237, 255, 263, 266, 267, 279–285,
 301, 306, 353, 363, 410, 412, 451
 domain 246, 250, 251, 262, 272, 275, 348
Ligand-substrate analogues 98
Linear integration 270
Lipinski's rule of 5 107, 219
Lipofection
Lipophilicity v, 217–225, 255, 405
Liver X receptors 246
Luminescence 119, 252, 257, 343

M

- Mass Spectrometry (MS)
 tandem MS
 triple quadrupole MS 21
Material design 114
Meta-binding site 288, 292
Methylation 253, 347, 348, 421
Methyllysine readers 348–351, 365
Model development 114, 116, 118, 122,
125, 387–400
Mold2 descriptors 118

- Molecular cloning 91, 92
Molecular descriptors 114–121, 136, 356
Molecular docking
 assessment 78–83
 induced fit 169, 233, 363, 451, 454, 456
 inverse 230, 231, 233, 247
Molecular dynamics (MD)
 steered MD 198, 202
 supervised (SuMD) 287–296
Molecular hybridization 7
Molecular modeling 136, 292, 317, 319,
412, 413, 432, 435, 438, 440
Molecular replacement 98, 253
MolProbity 98
MOLREP 98
Monoacylglycerol Lipase (MAGL) v, 335–344
MOSFLM 96
Multi-angle laser light scattering (MALLS) 94
Multiple reaction monitoring (MRM) 375, 379
Multi-target ligands
Murine
 fibroblast 144, 150, 343
 macrophages 144, 149, 150

N

- Nanoinformatics 115, 116, 136
Naringenin 372, 373, 378–380, 382
Native protein 61, 92, 94, 99, 319
Natural product vi, 384
Nuclear magnetic resonance (NMR) 3, 4, 420
 biomolecular v, 299–314
 data 12, 428, 449
 liquids 417, 418
 ^1H liquid state
 reactions in NMR tubes 417–428
 saturation transfer difference NMR 49–62
 two-dimensional (2D)
 2D NOESY 4
 2D ROESY 4, 420
 2D TOCSY 3, 4
Nuclear receptor v, 245–260

O

- Olmesartan 421–425, 427, 428, 449,
451, 452, 454–457
Olmesartan methyl ether 422, 423, 428,
451, 452, 456, 457
Omega-3 lipids
Omega software 265
Open-access data 91
Open-source 114, 115, 136, 202, 323
Organocadmium reagents 280, 281

P

1-Palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC) bilayers..... 2, 4, 12

Partial Least Squares (PLS)
analysis 391
factors..... 392, 393, 397, 399, 400

Pearson-R 393

Peptide
bond 98
synthesis 19, 373

Peroxisome proliferator-activated receptors 249

Pharmaceutical efficiency 90

Pharmacological characterization 422, 423, 428

Pharmacophore 390, 391, 393
common hypothesis 320, 321, 388, 392, 394
dynamic 320, 321
features
aromatic ring (R)..... 390
hydrogen bond acceptor (A) 393
hydrogen bond donor (D) 391
Hydrophobe (H)..... 390
negative ionizable (N) 390
Positive ionizable (P) 390
generation 323, 327, 329, 352, 359
model 35, 36, 300, 311, 319–321, 323, 326–328, 352, 354–356, 364, 409, 413
modeling 34, 36, 300, 311, 319, 320, 325, 395, 435
screening 272, 328, 329, 356, 358, 364

PHASE 262, 352, 387–400

PHASER 98

Phenotypic screening

PHENIX 98

PHYRE2 102

Phytochemicals

PISA server 98

Plasma stability 373, 379, 384

Platelet aggregation 372, 374, 381–384

Platelet aggregometry 381

Platelet receptors 372, 373

Poly-pharmacology 229, 231–234, 236, 237, 241

Polyunsaturated fatty acids (PUFAs) 378

Post-translational modifications (PTMs) 92, 102, 348

Precipitation 95, 105, 161

Prediction 67, 102, 114, 120, 122, 125, 126, 136, 145, 157, 158, 165, 212, 219, 231, 233, 262, 263, 273, 363, 388, 392, 410, 411, 413, 435, 439, 440

Predictive activity 392

Principal component analysis (PCA)..... 372, 373, 375–378, 384

Progress of a reaction..... 421

Promastigotes 143, 147

Protease-activated receptor 1 (PAR1) 372, 375

Protein Data Bank (PDB) 36, 38–40, 69, 70, 72–78, 86, 99, 167, 212, 231, 264, 266, 272, 287, 289, 291, 319–321, 323, 325, 327, 328, 337, 352, 354, 359, 406, 408, 409, 412, 413, 434, 440, 441, 443, 452, 455, 456

Protein engineering 93, 102

Protein expression 92, 93, 104, 302, 308

Protein labeling 304, 306

Protein–ligand complexes 44, 195–197, 199, 202, 203, 264, 301, 305, 318–320, 325, 327, 435, 439, 441, 458

Protein–ligand interactions 166, 167, 170, 205, 263, 287, 296, 299–301, 304, 311–313, 318, 320, 418, 435, 457

Protein–protein interactions (PPI) 290, 300, 309–310, 437

Proteins 1, 17, 33, 49, 67, 90, 146, 166, 180, 231, 245, 262, 287, 299, 317, 337, 348, 387, 404, 418, 431, 449

Protein purification 93, 94, 104, 302

Protonation state 36, 39, 86, 98, 105, 169, 234, 265, 273, 323–325, 355, 360, 363, 408, 438–442

PubChem 113, 115, 116, 119, 128, 132–136, 262

P2Y12 receptor 295, 372, 373, 375

Q

Q-squared 392–394

Quantitative structure activity relationships (QSAR)
three dimensional (3D) 68, 394, 395, 398

Quantitative structure toxicity relationships (QSTR) 120

R

Raman spectroscopy 23, 24

Rate of a reaction 420, 424–426

Rational drug design v, 1–16, 34, 90–108, 139, 195, 261, 387, 404, 407, 417–428, 449, 451

Reaction rate constant 424

Receptor targeting 230, 247, 249, 252, 259, 435, 437

Recognition pathway 290

Regioselectivity

Relaxation delay 56, 57, 305–308, 314, 423

Relibase+ 98

Renilla luciferase 251, 252

Reporter gene
assay 250–258

Response element (RE) 246, 250, 251

Retention factors 220–222, 224, 225
Retinoid X receptors (RXR) 246, 249
Retinoic acid receptor 246
Robetta 102
ROCS software 262, 264, 268, 269,
271, 272, 274, 337
R-squared 392–394, 399

S

Sampling optimization 271
Secondary structure 23, 24, 92, 94, 418
Selectivity 249, 253, 255, 259, 398, 400
Sequence homology 98, 102, 166, 168,
352, 408, 449, 450, 452, 456
Sequence prediction tool 102
Sequences 2, 4, 18, 21, 22, 50, 56,
58, 70–72, 77–79, 81–84, 91, 92, 98, 102,
168, 172, 303, 307, 311, 314, 347, 408, 413,
418, 424, 437, 449, 454
Sigma (σ) receptor 279–285
Similarity search 352, 353, 361, 362, 404
Sitting drop 104
Small Angle X-ray Scattering (SAXS) 90
Solubility 22, 54, 93, 94, 96, 102, 104–106,
161, 217, 225, 255, 256, 303, 375, 409
Solvent molecules 9, 45, 70, 73, 98, 106, 205
Spindlin1 v, 347–365
Stability 2, 91, 93, 104, 105, 195, 196,
198, 204, 205, 212, 302, 303, 312, 320, 393,
422, 450, 451
 π - π stacking interactions 99
Standard deviation (SD) 126, 155, 160, 202,
220, 234, 309, 326, 343, 355–357, 360, 362,
384, 391–393
Statistical analysis 98, 114, 128, 157, 160, 310
Stereochemistry 98, 99, 388
Stoichiometry of the reaction 427
Structural bioinformatics 98, 432
Structural biology v, 90–108, 166, 287, 432
Structural homology vi, 98
Structural properties 114, 419
Structural stability 195, 196, 198
Structure-based drug design (SBDD) 67, 90,
196, 287, 349, 363, 387, 404, 410
Structure elucidation 417, 422
Superposition 170
Swiss-Model 102, 413
Synchrotron radiation sources (SRS) 96

T

Target fishing 229
Terbium cryptate 179
Test sets 119, 122, 127, 128, 320, 327,
390–392, 399, 400
Thioflavin T (Th T) 24, 27, 28
Thrombin receptor activating peptide-6 (TRAP-6) ... 382
Thrombosis
Titration 50, 220, 255, 300, 303,
304, 309, 310, 314
Training set 124, 126, 127, 222, 223,
263, 390–392, 397, 400
Transactivation assay 250
Transfection 251, 256
TRAPP 98
Tree-based partitioning technique 391
Triple antiplatelet activity 372
Trypanosomiasis 139
T-shaped edge-to-face interactions 99

U

Ultrasound baths 105

V

van der Waals 34, 45, 99, 170, 236, 267,
271, 350, 443, 454
Vapor diffusion 96, 104
Variants 51, 231, 390, 391, 396
Virtual screening (VS) 68, 114, 126, 136,
165–173, 198–200, 210, 213, 233, 252, 262,
265, 270, 274, 275, 299, 300, 308, 311,
318–321, 323, 324, 327, 328, 337–338, 344,
347–365, 404, 405, 413, 432, 439

W

WEKA 114, 115, 119–122

X

XDS 96
X-ray crystallography 68, 86, 90, 262,
291, 319, 321, 352, 403, 435, 449

Z

Zebrafish 144, 145, 153
ZINC database 36, 37, 106, 133, 232,
233, 262, 353, 439